Every other symptom of menopause eventually settles on its own. This one does not. Left alone it progresses, quietly, for the rest of your life.
It is also, by some distance, the most reliably treatable thing here. Reported efficacy for local treatment runs around 80 to 90 percent, against about 75 percent for systemic treatment. And in November 2025 the US regulator asked manufacturers to remove the boxed warning from all estrogen products, including the low dose vaginal ones.
There is a reason this is the least discussed subject in women's medicine and it is not medical. Women do not raise it, and doctors do not ask. So it goes untreated for a decade in a woman who would have said yes immediately if anyone had offered.
What it actually is
Estrogen maintains the tissue of the vulva, vagina, urethra and bladder. When estrogen falls, that tissue becomes thinner, drier and less elastic, and the local environment changes. The consequences are a set that women rarely connect to each other:
- Dryness and burning, day to day, not only during sex.
- Pain during intercourse, which for many couples quietly ends their sex life without either of them naming why.
- Urinary urgency and frequency.
- Urinary tract infections that keep coming back. This is the one almost nobody knows belongs to the same cause. Women are given repeat courses of antibiotics for years while the actual driver goes unaddressed.
- Loss of drive, some of which is hormonal in its own right and some of which is simply the entirely rational response to discomfort.
Among women taking treatment for breast cancer the figures are higher still. The 2025 European Society of Endocrinology guideline puts it at 50 to 75 percent, with aromatase inhibitors the worst offenders. That group is also the group most likely to be told nothing can be done, which is not true.
What the evidence shows
The largest randomized trial in this field, published in JAMA Internal Medicine in 2018, assigned 302 postmenopausal women with vulvovaginal symptoms to a low dose vaginal estradiol tablet, a moisturizer, or placebo. It is an honest and much argued over trial, and it is worth reading with a specialist rather than from a headline.
A systematic review of 19 randomized trials including more than 4,000 patients found creams, inserts and rings all similarly effective at relieving symptoms. Endometrial safety has been shown in randomized trials of up to 52 weeks.
On the fear that stops most women: the doses involved are very small. Serum estradiol on the low dose ring runs around 5 to 10 picograms per milliliter, against roughly 5 in an untreated postmenopausal woman and 40 to 600 across a normal premenopausal cycle. That is the context in which the regulator removed the boxed warning in late 2025.
There are also non estrogen options with real trial support, including a vaginal preparation approved in 2016 for painful intercourse due to menopause, and an oral option used specifically for this indication.
What does not work, and what can harm
Laser devices are heavily marketed for this. In a randomized trial of 85 postmenopausal women, carbon dioxide laser and sham treatment produced similar improvement at 12 months, with similar quality of life scores. A second randomized trial of 49 women found the same. In July 2018 the US regulator issued a safety communication warning about vaginal burns, scarring, pain during intercourse and chronic pain with these devices.
That is an expensive, promoted, uncomfortable intervention that performed no better than sham in the trials built to test it. It is exactly the sort of thing a specialist saves you from.
If you have had breast cancer
This is where women are failed most often, and where the evidence has moved.
Non hormonal moisturizers and lubricants are first line for every woman with a breast cancer history, and one prospective study of 101 women with hormone receptor positive disease supports their use. Beyond that, a 2025 systematic review and meta analysis in the American Journal of Obstetrics and Gynecology pooled eight observational studies of breast cancer survivors and found no association between vaginal estrogen and recurrence.
That does not make it automatic, and it absolutely does not make it a decision to take from a website. It makes it a decision to take with your oncologist and a hormone specialist together, which is a conversation most women are never offered.
You will not be asked about this at your next appointment. Fifty percent prevalence and near zero disclosure is not a coincidence, it is what happens when both sides wait for the other to raise it. So raise it, or write to someone whose job is exactly this.
The thing worth saying plainly
This is not vanity and it is not optional. It is comfort, intimacy, sleep, and not spending your sixties on repeat antibiotics. It is also, unusually in this field, a problem with a high success rate and a low risk profile.
You do not have to say the words out loud to a stranger in a waiting room. Write it to the specialist instead, in English or Dutch, and have it dealt with properly.